Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) Operating cash flow

Alert me on Operating cash flow

Viatris Inc.'s operating cash flow for fiscal 2025 was $2.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.3B. Over the past ten years it has ranged from $1.2B (fiscal 2020) to $3.0B (fiscal 2021); the current reading is higher than 64% of that period. Viatris Inc. ranks 4th of 86 Drug Manufacturers Specialty & Generic companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $2.3B 0.56%
FY2024 $2.3B (20.59%)
FY2023 $2.9B (3.30%)
FY2022 $3.0B (0.59%)
FY2021 $3.0B 144.92%
FY2020 $1.2B (31.71%)
FY2019 $1.8B (22.97%)
FY2018 $2.3B 13.41%
FY2017 $2.1B 0.86%
FY2016 $2.0B 1.93%

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $381.8M (1.67%)
Mar 2026 $388.3M (52.40%)
Dec 2025 $815.8M 9.52%
Sep 2025 $744.9M 239.05%
42 more quarters

Against its own ten years

Low $1.2B High $3.0B
Ten-year median $2.3B
Current reading's percentile 64

Operating cash flow against peers

Company Operating cash flow
TAK Takeda Pharmaceutical Co. compare $11.1B
HLN Haleon PLC Sponsored ADR compare $4.8B
ZTS Zoetis Inc. compare $2.8B
VTRS Viatris Inc. $2.3B
TEVA Teva Pharmaceutical Industries Ltd. compare $1.9B
UTHR United Therapeutics Corporation compare $1.7B
NBIX Neurocrine Biosciences, Inc. compare $898.1M
ELAN Elanco Animal Health Incorporated compare $617.0M
RDY Dr. Reddy's Laboratories Ltd compare $426.0M

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on VTRS